Skip to main content
. Author manuscript; available in PMC: 2009 Nov 1.
Published in final edited form as: Pharmacogenet Genomics. 2008 Nov;18(11):955–965. doi: 10.1097/FPC.0b013e32830efdd4

Figure 2.

Figure 2

A) Survival tree analysis in NER pathway in stages IIIB/IV NSCLC patients treated with first line cisplatin-based chemotherapy; B) Cox proportional model in stages IIIB/IV NSCLC patients treated with first line cisplatin-based chemotherapy based on the survival tree analysis in NER Pathway; C) Kaplan-Meier curves in stages IIIB/IV NSCLC patients treated with first line cisplatin-based chemotherapy based on survival tree analysis in NER Pathway for selected nodes.